Loading...
XNAS
AYTU
Market cap22mUSD
Oct 08, Last price  
2.05USD
1D
0.00%
1Q
-8.89%
IPO
-99.99%
Name

Aytu Biopharma Inc

Chart & performance

D1W1MN
XNAS:AYTU chart
P/E
—
P/S
0.38
EPS
—
Div yield, %
—
Shrs. gr., 5y
71.10%
Rev. gr., 5y
-2.59%
Revenues
58m
-13.27%
001,750001,7501,75058,929261,7822,562,4453,221,5903,660,0007,320,35727,632,00065,632,00096,669,000107,399,00065,183,00066,382,00057,570,000
Net income
-14m
L+5.09%
-48,954-57,173-58,894-60,270-136,802-59,675-57,318-5,578,690-7,723,404-28,180,084-22,508,304-10,187,863-47,166,950-13,621,000-58,289,000-108,779,000-17,051,000-15,844,000-13,562,000-14,252,000
CFO
3m
P
-27,916-44,799-46,631-43,375-64,818-37,849-37,704-5,501,962-6,634,214-10,657,449-13,829,652-15,940,322-13,831,377-28,373,887-25,964,000-28,823,000-5,129,000-1,388,000-1,937,0003,281,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Aytu BioPharma, Inc. is a specialized pharmaceutical firm dedicated to advancing and marketing innovative therapeutic drugs and consumer health products, serving both domestic U.S. and international markets. Its commercialized portfolio includes several treatments for Attention Deficit Hyperactivity Disorder (ADHD): Adzenys XR-ODT, prescribed for patients aged 6 and up; Cotempla XR-ODT, tailored for individuals between 6 and 17 years old; and Adzenys ER, an oral liquid formulation also for those 6 years and older. Additionally, the company offers Karbinal ER, an oral carbinoxamine suspension for managing seasonal and perennial allergies. It also provides Poly-Vi-Flor and Tri-Vi-Flor, which are prescription vitamin supplements designed for infants and children with fluoride deficiencies. Other products include Tuzistra XR, a prescription cough suppressant oral suspension containing codeine polistirex and chlorpheniramine polistirex, and ZolpiMist, an oral spray indicated for addressing insomnia. Founded in 2015, the company was previously known as Aytu BioScience, Inc. before officially changing its name to Aytu BioPharma, Inc. in March 2021. Its corporate headquarters are located in Englewood, Colorado.

Key people

David A. Green
Chief Financial Officer, Treasurer, Secretary · since 2017
Jarrett T. Disbrow
Chief Operating Officer · since 2016
Matthew V. Phillips
Executive Vice President - Commercial Operations · since 2019
Ketan Bhupatrai Mehta
Director · since 2018
Gary V. Cantrell
Independent Director · since 2016
Carl C. Dockery
Independent Director · since 2016
IPO date
Oct 20, 2017
Employees
164
Domiciled in
US
Incorporated in
US
Legal address
C/O Corporation Service Company
2711 Centerville Road
Suite 400
Wilmington, DE 19808
US
Headquarters
16200 West Country Road 18E
Loveland, CO 80537
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑062025‑062024‑062023‑062022‑062021‑062020‑062019‑062018‑062017‑06
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT